))
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
Manage episode 427896111 series 2838329
Conteúdo fornecido por VJHemOnc. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por VJHemOnc ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Meeting and the 29th Congress of the European Hematology Association (EHA).
You will hear from Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, who discusses updated data from the MagnetisMM-3 trial (NCT04649359) of elranatamab and real-world findings from a French compassionate use program using this agent. Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, provides insights into the real-world step-up dosing of teclistamab to mitigate toxicities. Finally, Sundar Jagannath, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, discusses a matched adjusted indirect comparison (MAIC) of the novel bispecific linvoseltamab with teclistamab, and the sequencing of bispecific antibodies with CAR T-cells.
200 episódios
Compartilhar
